Share on StockTwits

The Spectranetics (NASDAQ:SPNC) SVP Kimberly Mcintosh Bridges sold 10,382 shares of the stock on the open market in a transaction dated Wednesday, September 3rd. The stock was sold at an average price of $29.38, for a total transaction of $305,023.16. Following the transaction, the senior vice president now directly owns 500 shares in the company, valued at approximately $14,690. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.

Several analysts have recently commented on the stock. Analysts at Zacks upgraded shares of The Spectranetics from an “underperform” rating to a “neutral” rating in a research note on Tuesday, July 29th. They now have a $27.30 price target on the stock. Analysts at Canaccord Genuity raised their price target on shares of The Spectranetics from $27.00 to $29.00 in a research note on Monday, July 21st. They now have a “buy” rating on the stock. Two research analysts have rated the stock with a sell rating, two have assigned a hold rating and four have assigned a buy rating to the stock. The stock currently has a consensus rating of “Hold” and an average price target of $27.41.

The Spectranetics (NASDAQ:SPNC) traded down 1.71% during mid-day trading on Thursday, hitting $28.22. 298,746 shares of the company’s stock traded hands. The Spectranetics has a one year low of $15.54 and a one year high of $31.94. The stock has a 50-day moving average of $27.19 and a 200-day moving average of $25.61. The company’s market cap is $1.176 billion.

The Spectranetics (NASDAQ:SPNC) last posted its quarterly earnings results on Thursday, July 24th. The company reported $0.06 EPS for the quarter, beating the Thomson Reuters consensus estimate of ($0.09) by $0.15. The company had revenue of $43.60 million for the quarter, compared to the consensus estimate of $42.60 million. During the same quarter in the prior year, the company posted ($0.02) earnings per share. The company’s quarterly revenue was up 10.5% on a year-over-year basis. Analysts expect that The Spectranetics will post $-0.33 EPS for the current fiscal year.

The Spectranetics Corporation develops, manufactures, markets and distributes single-use medical devices used in minimally invasive procedures within the cardiovascular system.

Receive News & Ratings for The Spectranetics Co Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for The Spectranetics Co and related companies with Analyst Ratings Network's FREE daily email newsletter.